145
Registered trials
58
Recruiting
77
Completed trials
88
Sponsors
24
Countries
Phase III:
38
Phase II/III:
6
Phase II:
71
Phase I/II:
18
Phase IV:
7
Phase I:
1
Phase I (Other):
1
Phase I (FiH):
2
Other:
1
Oversight events:
2 serious breaches
4 temporary halts
5 urgent safety measures
4 unexpected events
4 corrective measures
across 17 trials
View oversight register →
Indications tested
Non-small cell lung cancer
8
Small cell lung cancer extensive stage
8
Triple negative breast cancer
7
Hepatocellular carcinoma
5
Small cell lung cancer
4
Non-small cell lung cancer metastatic
3
Non-small cell lung cancer stage IV
3
HER2 positive breast cancer
3
Non-small cell lung cancer stage IIIB
2
Bladder cancer
2
Colorectal cancer
2
Non-small cell lung cancer stage III
2
Sponsors using this IMP
F. Hoffmann-La Roche AG
29
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
5
Institut Gustave Roussy
5
Intergroupe Francophone De Cancerologie Thoracique
4
Centre Leon Berard
3
Exelixis Inc.
3
Unicancer
3
AbbVie Deutschland GmbH & Co. KG
2
AIO-Studien gGmbH
2
Boehringer Ingelheim Espana S.A.
2
Boehringer Ingelheim International GmbH
2
Bristol-Myers Squibb Services Unlimited Company
2
All trials — page 3
145 total-
DRUP trial Recruiting
Showing 49–72 of 145 trials